Syschem (India) Past Earnings Performance
Past criteria checks 2/6
Syschem (India) has been growing earnings at an average annual rate of 43.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 25.3% per year. Syschem (India)'s return on equity is 2.1%, and it has net margins of 0.4%.
Key information
43.9%
Earnings growth rate
40.7%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 25.3% |
Return on equity | 2.1% |
Net Margin | 0.4% |
Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Syschem (India) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,854 | 12 | 70 | 0 |
31 Mar 24 | 2,335 | 28 | 64 | 0 |
31 Dec 23 | 2,024 | 34 | 60 | 0 |
30 Sep 23 | 1,855 | 53 | 55 | 0 |
30 Jun 23 | 1,645 | 55 | 50 | 0 |
31 Mar 23 | 1,306 | 45 | 47 | 0 |
31 Dec 22 | 961 | 66 | 46 | 0 |
30 Sep 22 | 725 | 35 | 46 | 0 |
30 Jun 22 | 624 | 5 | 43 | 0 |
31 Mar 22 | 657 | -17 | 49 | 0 |
31 Dec 21 | 667 | -68 | 50 | 0 |
30 Sep 21 | 758 | -74 | 50 | 0 |
30 Jun 21 | 823 | -67 | 44 | 0 |
31 Mar 21 | 744 | -56 | 45 | 0 |
31 Dec 20 | 742 | -35 | 39 | 0 |
30 Sep 20 | 717 | -35 | 34 | 0 |
30 Jun 20 | 811 | -23 | 33 | 0 |
31 Mar 20 | 881 | -19 | 33 | 0 |
31 Dec 19 | 954 | -18 | 33 | 0 |
30 Sep 19 | 900 | -1 | 31 | 0 |
30 Jun 19 | 950 | 3 | 30 | 0 |
31 Mar 19 | 1,097 | 8 | 33 | 0 |
31 Dec 18 | 1,180 | 21 | 33 | 0 |
30 Sep 18 | 1,239 | 21 | 29 | 0 |
30 Jun 18 | 1,012 | 13 | 25 | 0 |
31 Mar 18 | 766 | 3 | 29 | 0 |
31 Dec 17 | 454 | 2 | 20 | 0 |
30 Sep 17 | 321 | -11 | 19 | 0 |
30 Jun 17 | 214 | -13 | 11 | 0 |
31 Mar 17 | 135 | -15 | 8 | 0 |
31 Dec 16 | 9 | -5 | 1 | 0 |
30 Sep 16 | 10 | -21 | 2 | 0 |
30 Jun 16 | 8 | -20 | 0 | 0 |
31 Mar 16 | 36 | -22 | 3 | 0 |
31 Dec 15 | 99 | -19 | 3 | 0 |
30 Sep 15 | 105 | -14 | 5 | 0 |
30 Jun 15 | 115 | -28 | 6 | 0 |
31 Mar 15 | 114 | -39 | 7 | 0 |
31 Dec 14 | 101 | -53 | 13 | 0 |
30 Sep 14 | 136 | -37 | 15 | 0 |
30 Jun 14 | 170 | -17 | 13 | 0 |
31 Mar 14 | 184 | 6 | 20 | 0 |
31 Dec 13 | 193 | 8 | 29 | 0 |
Quality Earnings: 531173 has high quality earnings.
Growing Profit Margin: 531173's current net profit margins (0.4%) are lower than last year (3.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531173 has become profitable over the past 5 years, growing earnings by 43.9% per year.
Accelerating Growth: 531173's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 531173 had negative earnings growth (-77.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).
Return on Equity
High ROE: 531173's Return on Equity (2.1%) is considered low.